Repligen | RGEN - Sales Revenues


Repligen reported $197.91M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agilent USD 1.8B 63M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
Bio Techne USD 295.9M 9.34M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Bruker USD 977.2M 116.7M Dec/2025
Charles River Laboratories USD 994.2M 5.8M Dec/2025
Danaher USD 6.84B 790M Dec/2025
Dentsply International USD 961M 57M Dec/2025
General Electric Aerospace USD 11.87B 560M Dec/2025
Henry Schein USD 3.4B 60M Dec/2025
Illumina USD 1.16B 80M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Mettler Toledo International USD 1.13B 100M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Repligen USD 197.91M 8.91M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Standard Biotools USD 23.8M 4.24M Dec/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Waters USD 932M 132M Dec/2025
West Pharmaceutical Services USD 805M 400K Dec/2025